Valeant Canada announces an investment of $10 million in Laval facility to increase and secure its export capacity

LAVAL, QC, June 13, 2016 /CNW Telbec/ - Valeant Canada continues the expansion of its Canadian manufacturing and export capacity with a $10 million investment in its Laval, Quebec headquarters to enhance the site's manufacturing and export capabilities.

Today's announcement, the fourth notable investment announcement by Valeant in Canada in recent weeks, includes modernization of the plant with enhanced manufacturing technology to ensure robust security of Valeant-manufactured products as they move through international distribution channels.

The investment announced today in our Laval plant will ensure compliance with U.S. regulatory requirements and maintain the facility's ability to service significant North American manufacturing mandates. It currently exports 75% of its products into markets across the continent. The upgrades for product manufacturing will take place by the end of 2016.  

"Today's announcement demonstrates Valeant's strong intention of growing its manufacturing   base in Canada and using it to export important health products." said Jacques Dessureault, President and General Manager of Valeant Canada. "We are proud to be a Canadian-headquartered company.  The Laval facility plays a critical role in advancing healthcare technology both in Canada, and around the globe." 

Last week, Valeant announced the transfer of the North American manufacturing mandate of Arestin to Laval, an investment of a further $2.5 million. This transfer of Arestin^®, an antibiotic treatment for periodontal disease, will create 15 new engineering and production jobs and builds upon the transfer of Jublia^® production to Quebec earlier this year.  Since 2012, Valeant has transferred numerous technologies to Laval, resulting in the production of 67 new products.

These recent investments in innovative manufacturing will ensure that the Valeant production facility in Laval remains competitive in the global marketplace. 

"With this investment we will boost Valeant Canada's ability to produce a broad range of prescription products, with exceptional quality controls, for an increasingly global clientele," said Jean Habel, Member of the National Assembly for Sainte-Rose. 

"The riding of Sainte-Rose is pleased to count on Valeant to maintain and create quality jobs in Québec."

About Valeant Canada

Valeant Canada is a subsidiary of Valeant Pharmaceuticals International Inc., a multinational specialty pharmaceutical company that develops, manufactures, and markets a broad range of pharmaceutical products, primarily in the areas of dermatology, eye health, cardio-metabolic, and neurology. More information about Valeant Canada can be found at www.valeantcanada.com.

SOURCE Valeant Canada

Sébastien Beauchamp, Valeant Canada LP, Tel. : [phone], Courriel : [email protected]